The evolution of angiotensin blockade in the management of cardiovascular disease

Canadian Journal of Cardiology

Volumn 26, Issue SUPPL. E, 2010, Pages 7E-13E

  Nantel, Pierre ^a   de Cotret, Paul René ^b,c  

^a Hotel Dieu de Sorel   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; End organ disease; End organ protection; Renin angiotensin system

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; INDAPAMIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PERINDOPRIL; RAMIPRIL; RENIN; SARALASIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS (TOPIC); MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; URINARY ALBUMIN EXCRETION; URINARY EXCRETION; CARDIOVASCULAR DISEASE; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HUMANS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79958800898     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)71168-5     Document Type: Article

References (75)

1. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998;19(Suppl J):J2-J6.
2. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13:9-20.
3. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-87.
4. Ruster C, Wolf G. Renin-angiotensin aldosterone system and progression of renal disease. J Am Soc Nephrol 2006;17:2985-91.
5. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005;99:S57-S65.
6. Tigerstedt R, Bergman PG. Niere und Kreislauf. Scand Arch Physiol 1898;8:223-71.
7. Goldblatt H. Experimental hypertension induced by renal ischemia: Harvey Lecture, May 19, 1938. Bull N Y Acad Med 1938;14:523-53.
8. Braun Menéndez E, Fasciolo JC, Leloir LF, Muñoz JM. La substancia hipertensora de la sangre del riñón isquemiado. Rev Soc Arg Biol 1939;15:420-5.
9. Page IH, Helmer OM. A crystalline pressor substance, angiotonin. Proc Center Soc Clin Invest 1939;12:17.
10. Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP. The existence of two forms of hypertension. J Exp Med 1954;99:275-82.
11. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararca. Br J Pharmacol Chemother 1965;24:163-9.
12. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 1974;291:817-21.
13. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-70.
14. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978;58:770-5.
15. Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin-potentiating peptides from Bothrops jararca venom. Biochemistry 1970;9:2583-93.
16. Ferreira SH, Greene LH, Alabaster VA, Bakhle YS, Vane JR. Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 1970;225:379-80.
17. Atkinson AB, Robertson JI. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979;2:836-9.
18. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
19. Brunner HR, Gavras H, Laragh JH, Keenan R. Angiotensin II blockade in man by Sar1-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973;2:1045-8.
20. Brunner HR, Gavras H, Laragh JH, Keenan R. Hypertension in man: Exposure of the renin and sodium components using angiotensin II blockade. Circ Res 1974;34(Suppl I):I35-I43.
21. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H. Congestive heart failure in normotensive man: Haemodynamics, renin, and angiotensin II blockade. Br Heart J 1978;40:1134-42.
22. Adam M. Integrating research and development: The emergence of rational drug design in the pharmaceutical industry. Stud Hist Philos Biol Biomed Sci 2005;36:513-37.
23. Streeten DHP, Anderson GH, Freiberg JM, Dalakos TG. Use of an angiotensin II antagonist (saralasin) in the recognition of angiotensinogenic hypertension. N Engl J Med 1975;292:657-62.
24. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994;89:493-8.
25. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: Distribution, signalling and function. Clin Sci (Lond) 2001;100:481-92.
26. Vinson GP, Ho MM, Puddefoot JR. The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems. Mol Med Today 1995;1:35-9.
27. Jackson EK. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw Hill, 2006:789-821.
28. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51:519-28.
29. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
30. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction. N Engl J Med 1992;327:669-77.
31. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
32. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
33. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
34. Braunwald E, Domanski MJ, Fowler SE, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
35. Khan NA, Hemmelgarn B, Herman RJ, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 2008;24:465-75.
36. Patel A; for the ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-40.
37. Gaudron P, Eilles C, Ertl G, Kochsiek K. Early remodelling of the left ventricle in patients with myocardial infarction. Eur Heart J 1990;(11 Suppl B):139-46.
38. Jeremy RW, Allman KC, Bautovitch G, Harris PJ. Patterns of left ventricular dilation during the six months after myocardial infarction. J Am Coll Cardiol 1989;13:304-10.
39. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-6.
40. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;1:255-9.
41. Køber L, Torp-Pedersen C, Carlsen JE; for the Trandolapril Cardiac Evaluation (TRACE) study group. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
42. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.
43. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997;349:1493-7.
44. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
45. Ruggenenti P, Fassi A, Parvanova AI, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
46. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
47. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
48. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-6.
49. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64.
50. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001;87:3C-9C.
51. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: Rationale and design. Blood Press 1998;7:176-83.
52. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-31.
53. Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press 2001;10:83-91.
54. Dahlöf B, Devereux RB, Kjeldsen SE, et al; for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study [LIFE): A randomized trial against atenolol. Lancet 2002;359:995-1003.
55. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in Acute Myocardial Infarction trial (VALIANT): Rationale and design. Am Heart J 2000;140:727-50.
56. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
57. Yusuf S, Teo KK, Pogue J, et al; for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
58. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
59. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) - rationale and design. J Card Fail 1999;5:276-82.
60. McMurray J, Östergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fracture heart failure: Baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003;5:261-70.
61. McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE-inhibitor: The CHARM-Added trial. Lancet 2003;362:767-71.
62. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE-inhibitors: The CHARM-Alternative Trial. Lancet 2003;362:772-6.
63. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: The CHARM-Preserved Trial. Lancet 2003;362:777-81.
64. Young JB, Dunlap ME, Pfeffer MA, et al. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-26.
65. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003;362:759-66.
66. Lindholm LH, Ibsen H, Borch-Johnsen K, et al; for the LIFE study group. Risk of new onset-diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
67. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 2002;106:672-8.
68. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
69. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
70. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
71. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.
72. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
73. Solomon SD, Appelbaum E, Manning WJ, et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7.
74. Duprez DA, Davis P, Botha J. The AGELESS Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients > 65 years of age with systolic hypertension. Circulation 2008;118:S886-7.
75. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: The potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009;10:65-76.